Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

The Return of Cardiovascular Information Trial (RECITE) (RECITE)

11 juni 2026 bijgewerkt door: Amil Shah, University of Texas Southwestern Medical Center

The goal of this behavioral interventional trial is to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants enrolled in the Dallas Heart Study (DHS) cohort. The main questions it aims to answer are:

  • What are the effects of presenting health information in a coarse vs. granular manner? (This question will be measured by randomizing participants to two groups: one group will get a cover letter with their health information communicated in a more detailed manner, while another group will receive a cover letter which presents their health information in a coarse manner. Two letters will be sent containing the same information regarding their results. 4 months after the second letter, participants will be asked about changes made for their health after receiving the letter)
  • How curious are people about bettering their health after being presented their health information? (This question will be measured by placing QR codes linking educational health videos on each cover letter. Each letter will be sent twice with exactly the same health information but with new QR (Quick Response) codes. QR code use will be tracked by the study staff)

Researchers will assess whether participants who received different style letters had different responses to their health behaviors and medication afterward and will measure this with a follow-up phone call. Researchers will also assess the use of QR codes showing health-related videos (about physical activity, heart-healthy diet, diabetes medication, statin medication) by sending out two different letters with the same health information and format, but with different QR code-linked videos.

Participants will:

  • Receive two letters in the mail, 4 weeks apart, containing their results from the Dallas Heart Study's 4th visit. The cover letter for this report will be randomized and will contain coarse vs. granular presentations of the participant's heart health risk.
  • Receive a follow up call after 4 months to assess: whether they received the letter, whether they understood the information provided, whether they made any health changes after receiving the letter, whether they saw a healthcare provider after receiving the letter, whether the letter prompted a new diagnosis by a doctor, and whether the participant made any medication changes after the letter.

Studie Overzicht

Gedetailleerde beschrijving

The Return of Cardiovascular Information Trial (RECITE) is a multi-factorial, adaptive randomized behavioral intervention trial which aims to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants attending the Dallas Heart Study (DHS) fourth visit (DHS-4). This embedded behavioral intervention trial will evaluate two independent intervention components-risk information presentation and personalized action-planning support-to identify communication strategies that most effectively motivate and sustain healthy behavior change. The randomized intervention will be receipt of one of two different cover letter templates for the participant post-visit return-of-results letter.

Intervention Components:

The two primary treatment arms differ only in how one's health data measured during the DHS clinic visit are presented in the cover letter. Each cover letter shows the participant's AHA PREVENT (American Heart Association Predicting Risk of Cardiovascular Disease EVENTS) Risk Score results based on assessments performed at the DHS Visit. The risk score representation provides each participant's score compared to the distribution among DHS participants at Visit 3 (2020-2024). Each letter also provides the participant's actual estimated 10-year CVD (Cardiovascular Disease) risk based on the PREVENT Risk Score. To evaluate whether simplified (coarse) or detailed (fine) presentation of risk information better motivates behavior change, participants will be randomized to template cover letters presenting summary risk information as either:

  • Arm 1, Coarse Risk Format: Participants receive the standard DHS-4 result report supplemented with visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes.
  • Arm 2, Fine Risk Format: Participants receive the same standard results report, but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0".

Each participant's result letter will be sent to them twice, initially approximately 8 weeks after their DHS Visit 4, and a second time 12 weeks after their visit. All participants will otherwise receive the same clinical test results and observational summaries, preceded by a cover letter, to ensure consistency with standard DHS return-of-results practices.

Each cover letter will also include text recommending that participants view a set of short, publicly available educational YouTube videos, published by reputable health sources such as the American Heart Association and Mayo Clinic, related to heart health and lifestyle behaviors. These recommendations will appear immediately above the video links. Each participant's cover letter, printed or emailed and irrespective of study arm, will have QR codes/short links to the educational videos as described below. The information will be identical for each participant, but the order in which these links are displayed in each cover letter will be randomized to reduce position bias/primacy effect. Each video link will be embedded as a unique URL (Uniform Resource Locator) tied to the participant's de-identified study ID (Identifier), which will allow the study to capture link clicks. Different QR codes/short-links will be provided in the cover letter to the first mailing (8 weeks after visit) and the second mailing (12 weeks after the visit).

Each video delivers practical, actionable guidance, such as:

  • How to plan and structure daily routines to increase physical activity
  • How to adopt and sustain healthy eating patterns
  • Educational information regarding the following medication categories: diabetic medication, hypertension medication, and medication for high cholesterol.

Each participant will also get a follow-up phone call 16 weeks after their DHS study visit. The following questions will be asked:

  • Did you get the full results report of your DHS visit? (Yes/No)

    1. If no, stop survey, ask participant "would you like us to resend it?" If yes, then we resend (after confirming preferred method/contact info)
    2. If yes, then continue with questions
  • Did you understand the information provided to you? (Yes/No/I don't know/Refused)
  • Did you make any health changes after receiving your results? (Yes/No/I don't know/Refused)

    1. If yes, what change did you make? (Exercise, diet, other (free text))

  • Did the results report prompt a visit to your / healthcare provider? (Yes/No/I don't know/Refused)
  • Did the results report prompt a new diagnosis of hypertension, diabetes, high cholesterol, or another condition by your healthcare provider? (Yes/No/I don't know/Refused)

    1. If yes, which? Check as many as apply: HTN (Hypertension), diabetes, high cholesterol, or other (free text)

  • Were there any changes made to your medication as a result? (Yes/no/I don't know/refused)

Each subject will be identified solely by their pre-established and de-identified Dallas Heart Study (DHS) study ID, and no PHI (Protected Health Information) will be utilized for this clinical trial. Each unique, de-identified participant ID will be linked to a unique, de-identified QR code and short link created using GitHub Enterprise secure software and internal tools. We track participant engagement through website clicks using a simple web-based system (GitHub + Google Sheets) to record when a selection of publicly available educational YouTube videos is accessed. Each video link directs participants to a secure webpage hosted in a GitHub repository and served via GitHub Pages, a widely used academic and open-source static web hosting service. Specifically, GitHub maintains a repository of static (fixed and unedited) HTML (HyperText Markup Language) files, which are made publicly accessible on the internet as individual web links through GitHub Pages. Each file will correspond to each participant's de-identified study ID and video, each containing a small JavaScript component. This allows the links to be shared with participants either as QR codes or as URLs to directly type into a web browser. When a participant accesses a link, the system records minimal metadata (de-identified study ID, video identifier, and timestamp) and then immediately redirects the participant to the intended video content. Click metadata is transmitted securely and in real-time using encrypted HTTPS (HyperText Transfer Protocol Secure) connections to a Google-hosted secure web app (via Google Apps Script), which writes the de-identified information to a private Google Sheet accessible only to authorized study personnel. We systematically create HTML files and QR codes for each HTML web link using Python libraries and each participant's de-identified study ID only. No protected health information, HIPAA identifiers, IP (Internet Protocol) addresses, or device-level data are collected or stored as any part of this process. The use of this system is considered minimal risk, as it does not involve activity beyond standard web navigation and collects only limited, non-identifiable engagement data. Participants do not have access to the underlying code, data storage location, or logs, and cannot modify or view collected data. The system does not install software, use cookies, or track user behavior beyond the single link-click event.

Studietype

Ingrijpend

Inschrijving (Geschat)

1500

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • Werving
        • UT Southwestern Medical Center
        • Contact:
          • Deepa Raj

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Attendance of the Dallas Heart Study-4 clinical visit
  • Participant confirms ability and willingness to utilize short links/QR codes during clinical visit

Exclusion Criteria:

  • Did not attend the Dallas Heart Study-4 clinical visit
  • Did not confirm ability and willingness to utilize short links/QR codes
  • Participants for whom a PREVENT-CVD score cannot be calculated (those who did not complete a laboratory collection, and/or height/weight measurements [for BMI calculation]), and/or BP assessment, and/or did not complete the medical history questionnaire)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm 1, Coarse Health Risk Format
Arm 1, Coarse Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes.
Participants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected.
Experimenteel: Arm 2, Granular Health Risk Format
Arm 2, Fine Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0".
Participants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
QR Code use for Educational Health Videos
Tijdsspanne: 3 weeks after first health results letter is sent
Number of clicks per link/QR code in the 3 weeks after Result Letter #1 sent
3 weeks after first health results letter is sent
Change in Educational Health Video Engagement
Tijdsspanne: 3 weeks following the second result letter is sent
Change in number of clicks per link/QR code in the 3 weeks after Result Letter #2
3 weeks following the second result letter is sent

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Self-reported health behavior changes
Tijdsspanne: 16 weeks after randomization

1. Self-reported behavior changes assessed at the 4 month (16 week) follow up phone call:

  1. Participant self-report of seeing physician based off of health results
  2. Participant self-report of making lifestyle changes based on their delivered health results
16 weeks after randomization

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of adverse events
Tijdsspanne: on an annual basis from the time participants enroll in the Dallas Heart Study cohort until patient expires
This assessment will include adverse clinical events, including hospitalizations, acute myocardial infarction, stroke, or syncope which are assessed by annual health survey (phone/redcap survey-based), and if an event is endorsed, the participant is contacted with a request to receive their medical record. If they agree, the records are collected and the cardiologists will independently adjudicate the events as being definite/probable/indeterminate events. Additionally, each year Dallas Fort-Worth (DFW) hospital council foundation and CDC national death index data are queried for inpatient hospitalizations in the metroplex and mortality data, respectively.
on an annual basis from the time participants enroll in the Dallas Heart Study cohort until patient expires

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Amil M Shah, MD, MPH, University of Texas Southwestern Medical Center

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

22 april 2026

Primaire voltooiing (Geschat)

1 april 2028

Studie voltooiing (Geschat)

1 augustus 2028

Studieregistratiedata

Eerst ingediend

21 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

21 mei 2026

Eerst geplaatst (Werkelijk)

29 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

15 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

11 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • STU20260475
  • 1R01DK145081-01 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren